China SXT Pharmaceuticals Inc (NASDAQ:SXTC) — Stock Price
China SXT Pharmaceuticals Inc (NASDAQ:SXTC) is currently trading at $2.81 USD, up 11.51% today. Over the past 52 weeks, shares have ranged between $0.03 and $5.13. This page tracks China SXT Pharmaceuticals Inc's live share price on the NASDAQ exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. To see how efficiently this company converts equity into cash flow, see SXTC cash generation efficiency.
China SXT Pharmaceuticals Inc (SXTC) Stock Price Chart — Daily History & Trading Volume
The chart below tracks China SXT Pharmaceuticals Inc's daily closing share price and trading volume on the NASDAQ exchange over the past year, giving a clear view of recent price momentum and liquidity.
China SXT Pharmaceuticals Inc Income Statement — Revenue, Profit & Earnings by Year
China SXT Pharmaceuticals Inc's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Total Revenue | $1.07 Million | $1.74 Million | $1.93 Million | $1.97 Million | $2.60 Million |
| Cost of Revenue | $889.35K | $1.37 Million | $1.37 Million | $1.55 Million | $1.35 Million |
| Gross Profit | $183.28K | $367.43K | $553.97K | $426.27K | $1.25 Million |
| Research & Development | $178.76K | $191.39K | $184.19K | — | — |
| SG&A | $7.13 Million | $2.76 Million | $2.64 Million | $5.65 Million | $5.52 Million |
| Total Operating Expenses | $7.31 Million | $3.05 Million | $3.07 Million | $6.03 Million | $6.44 Million |
| Operating Income | $-7.12 Million | $-2.68 Million | $-2.52 Million | $-5.61 Million | $-5.19 Million |
| EBITDA | $-6.98 Million | $-2.57 Million | $-2.35 Million | $-5.21 Million | $-5.05 Million |
| EBIT | $-7.12 Million | $-2.66 Million | $-2.55 Million | $-5.46 Million | $-5.37 Million |
| Interest Expense | $62.97K | $648.22K | $544.28K | $476.78K | $36.70K |
| Income Before Tax | $-6.07 Million | $-3.30 Million | $-3.10 Million | $-5.93 Million | $-5.41 Million |
| Income Tax Expense | $130.84K | — | $3.00 | $476.78K | $328.15K |
| Net Income | $-6.21 Million | $-3.30 Million | $-3.10 Million | $-5.93 Million | $-5.74 Million |
China SXT Pharmaceuticals Inc Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes China SXT Pharmaceuticals Inc's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Total Assets | $34.75 Million | $21.66 Million | $23.13 Million | $29.55 Million | $33.55 Million |
| Total Current Assets | $34.51 Million | $21.30 Million | $14.23 Million | $19.52 Million | $22.45 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | — | $137.80K | — | — | — |
| Net Receivables | $3.23 Million | $1.90 Million | $1.35 Million | $1.34 Million | $3.37 Million |
| Inventory | $2.96 Million | $828.05K | $809.76K | $531.25K | $1.07 Million |
| Property, Plant & Equipment | — | — | — | — | $1.59 Million |
| Goodwill | — | — | — | — | — |
| Total Liabilities | $5.05 Million | $6.22 Million | $9.20 Million | $14.86 Million | $17.12 Million |
| Total Current Liabilities | $4.35 Million | $6.01 Million | $8.90 Million | $14.50 Million | $17.12 Million |
| Long-term Debt | $644.39K | $96.26K | $117.13K | $117.86K | — |
| Net Debt | $-27.06 Million | $-17.12 Million | $-9.42 Million | $-13.61 Million | $-4.78 Million |
| Total Stockholder Equity | $29.71 Million | $15.44 Million | $13.93 Million | $14.69 Million | $16.42 Million |
| Retained Earnings | $-34.22 Million | $-28.02 Million | $-24.71 Million | $-21.61 Million | $-15.69 Million |
China SXT Pharmaceuticals Inc Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how China SXT Pharmaceuticals Inc generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Operating Cash Flow | $-4.02 Million | $-2.35 Million | $-1.93 Million | $-80.76K | $-2.37 Million |
| Capital Expenditures | $4.00 | $2.02K | $7.06K | $70.68K | $62.49K |
| Free Cash Flow | $-4.02 Million | $-2.35 Million | $-1.94 Million | $-151.44K | $-2.44 Million |
| Investing Cash Flow | $-1.25 Million | $63.52K | $26.42K | $-12.30K | $-46.91K |
| Financing Cash Flow | $14.43 Million | $8.40 Million | $-2.62 Million | $2.94 Million | $1.63 Million |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | $5.31 Million | $0.00 | $352.10K | $554.57K | $2.33 Million |
| Depreciation | $143.22K | $82.30K | $203.25K | $250.16K | $320.01K |
| Change in Cash | $10.05 Million | $6.05 Million | $-5.29 Million | $1.80 Million | $-399.12K |
China SXT Pharmaceuticals Inc Earnings History — EPS Actual vs. Analyst Estimates
Track China SXT Pharmaceuticals Inc's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Oct 07, 2026 | — | — | — |
| Jul 30, 2026 | — | — | — |
| Dec 31, 2025 | -0.05 | 0.00 | — |
| Jul 31, 2025 | -1.02 | 0.00 | — |
| Mar 28, 2025 | -1.99 | 0.00 | — |
| Jul 18, 2022 | -2.03 | 0.00 | — |
| Jan 14, 2022 | -0.20 | 0.00 | — |
| Aug 13, 2021 | -0.27 | 0.00 | — |